Purpose; To determine the safety and activity of LY231514 (ALIMTA®, MTA, pemetrexed disodium, Eli Lilly and Co., Indianapolis, IN) in chemotherapy-naive patients with advanced pancreatic cancer.
Introduction
LY231514, a novel antifolate initially developed as an analogue of lometrexol [1] , undergoes extensive intracellular polyglutamation resulting in a prolonged intracellular half-life [2] . LY231514 targets several folaterequiring enzymes including thymidylate synthase (TS), dihydrofolate reductase, aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT) and glycinamide ribonucleotide formyltrasnferase (GARFT) [2] . LY231514 is 30-200 times more potent as an inhibitor of TS than of either AICARFT or GARFT suggesting that its clinical effects are mediated predominantly through TS inhibition. Nonetheless, the ability to inhibit multiple enzymes in a key metabolic pathway may limit the development of resistance. Indeed, MTA has significant antitumor activity in human leukemia and H630 colon carcinoma cell lines selected for TS amplification and resistance to raltitrexed or 5-fluorouracil (5-FU) [3] .
While phase I studies of LY231514 have investigated a variety of dosing schemes [4] , the once every 21 day schedule (maximum tolerated dose 600 mg/m 2 ) delivered the greatest dose intensity with an acceptable toxicity and pharmacokinetic profile. In addition, two patients with pancreatic cancer had objective responses with this schedule in the phase I study.
Patients and methods
Eligibility required histologically confirmed pancreatic adenocarcinoma that was bidimensionally measurable and either locally unresectable or metastatic. Additional requirements included: Eastern Cooperative Oncology Group (ECOG) performance status of $ 2 , calculated creatinine clearance 5 60 ml/min, white blood cell count > 3.5 x 10 9 /l, absolute granulocyte count > 2.0 x 10 9 /l, platelets > 100 x 10 9 /l, and hemoglobin > 9 g/1, bilirubin and prothrombin time within 1.5 times the upper limit of normal, alanine (ALT) and aspartate (AST) transaminase within three times the upper limit of normal. Patients with known liver metastases were eligible with ALT and AST up to five times normal. All patients gave written informed consent in accordance with local institutional review board guidelines.
Patients were excluded if they had prior chemotherapy, active infections, central nervous system metastases, clinically detectable third space fluid or another primary malignancy within the preceding five years (other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix). Prior radiation was allowed if completed at least one month before enrollment and if there was measurable disease outside the radiation port.
Treatment
Patients received LY231514 at a dose of 600 mg/m 2 as a 10-minute intravenous infusion once every 21 days. Treatment continued for a maximum 12 cycles of therapy or until disease progression or prohibitive toxicity (investigators discretion) was clearly demonstrated. Patients were assessed for response after every two cycles of therapy. Patients who developed grade 2 or higher skin reaction were treated with dexamethasone, 4 rag twice daily for six doses beginning the day before LY231514, with subsequent cycles. Dose modifications were stipulated for myelosuppression and mucositis.
Statistical analysis
A two-stage design was used in which response rates of 10% and 25% were considered low and high, respectively. If one or more of the first 13 patients responded, the trial would continue to a total of 35 qualified patients. This design had a power of 80% and a significance level of 0.06.
All patients were evaluable for toxicity. Only patients who received at least two doses of LY231514 were evaluable for response using the Southwest Oncology Group Criteria [5] . Time to treatment failure was defined as the time from study entry to the first observation of progressive disease, death or treatment discontinuation. Overall survival was defined as the time from study entry to death due to any cause. Time to event variables were estimated by the Kaplan-Meier product limit method [6] .
Results
From August 1995 to July 1997, 42 patients were enrolled. Thirty-five patients received at least two doses of LY231514 and were evaluable for response. Seven patients discontinued therapy after only one cycle of LY231514 and are evaluable for toxicity and survival only. Reasons for discontinuation included: clinical progression without radiologic confirmation (3), worsening renal function (1), death due to pre-existing chronic obstructive pulmonary disease (1), cerebrovascular accident (1), and patient request with clinically stable disease (1). The majority of patients (79%) had metastatic disease; 21% had locally unresectable disease. The median age was 60.3 years (range 37-77); 24 (57%) were male. ECOG performance scores of 0, 1 and 2 were recorded in 13, 21, and 7 patients, respectively; performance score was not recorded in 1 patient.
The frequency of common toxicities are detailed in Table 1 . Grade 3 or 4 neutropenia occurred in 41% of patients but never resulted in serious infectious complications (grade 1 only). Anemia was also serious with 31% of patients requiring transfusion; five (11.9%) patients required platelet transfusions. Cutaneous toxicity, often manifested as a severe lower extremity cellulitis, was most frequent nonhematologic toxicity. Dexamethasone was administered around subsequent cycles of therapy in 24 patients and limited further skin toxicity to grade 1 or less.
LY231514 was delivered for a median of two cycles of therapy (range 1-12). The mean dose of LY231514 received was 567 mg/m 2 /cycle. One complete (16.2 months duration) and one partial response were observed resulting in an overall response rate of 4.8% (95% confidence interval (95% CI): 0.6%-16.0%) in all eligible patients and 5.7% (95% CI: 0.7%-19.1%) for the 35 fully evaluable patients. In addition, stable disease was reported in 17 (40%) of eligible patients. Five patients with stable disease were still alive at the time of data analysis 19+, 17+, 16+, 10+ and 6+ months from study entry. The median time to treatment failure was 4.0 months (95% CI: 1.6-4.7 months) with an overall median survival of 6.5 months (95% CI: 4.5-10.5 months); 28% of patients were alive at 1 year.
Discussion
LY231514 demonstrates modest single agent activity in patients with advanced pancreatic cancer. Hematologic toxicity was significant and may limit the use of this dose and schedule in a palliative setting. Nonetheless, the median and one year survivals compare favorably to reported trials of other agents including gemcitabine. Though the one-year survival is encouraging, the potential influence of selection bias should not be underestimated. Our patients were generally healthy with a preserved performance status; the largest gemcitabine trial specifically selected patients with symptomatic disease making direct comparison troublesome [7] . The objective response rate alone would not support additional trials of this agent in pancreatic cancer but the prolonged survival of several patients with radiographically stable disease is intriguing. Gemcitabine provided significant clinical benefit (as measured by weight gain, improved performance status and decreasing pain) to one-quarter of treated patients despite achieving only a single digit objective response rate [7] . We believe this trial likewise illustrates the inadequacy of relying sole on objective tumor response as a measure of efficacy in pancreatic cancer. Potential clinical benefit noted by patients with stable disease is not reflected by the objective response rate. Quality of life indices, im-portant measures of efficacy in phase III trials, are difficult to interpret in phase II studies.
The prolonged stable disease seen in this trial provides hope for future development. Phase I trials of the combination of LY231514 and gemcitabine are ongoing. Evaluation of this combination in pancreatic cancer is warranted.
